| Followers | 832 |
| Posts | 119787 |
| Boards Moderated | 17 |
| Alias Born | 09/05/2002 |
Thursday, August 07, 2008 2:54:04 PM
NovoSeven Growth Continues
DKK 1600M = $330M ($1.3B annualized rate)
NovoSeven is a blockbuster, but continued growth at a
high rate is problematic due to the colossal cost per dose.
Lowering production cost is the impetus for GTC’s rFVIIa
program with LFB.
Source of graphic: Novo Nordisk
DKK 1600M = $330M ($1.3B annualized rate)
NovoSeven is a blockbuster, but continued growth at a
high rate is problematic due to the colossal cost per dose.
Lowering production cost is the impetus for GTC’s rFVIIa
program with LFB.
Source of graphic: Novo Nordisk
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
